EBT-101
Targeting HIV-infected cells in viral tissue reservoirs and systemic circulation.
Learn MoreExcision BioTherapeutics’ rapidly progressing pipeline comprises various programs targeting viral infectious diseases, including human immunodeficiency virus (HIV), herpes simplex viruses (HSV 1&2), and Hepatitis B.
HIV AAV9 Cas9 dual gRNA Therapeutic
Discovery/Validation | Preclinical | Cleared IND | Clinical Trials |
---|---|---|---|
Discovery/Validation Phase complete
|
Preclinical Phase complete
|
Cleared IND Phase in progress
|
Clinical Trials Phase not started
|
HSV AAV CRISPR/Cas dual gRNA Therapeutic
Discovery/Validation | Preclinical | Cleared IND | Clinical Trials |
---|---|---|---|
Discovery/Validation Phase complete
|
Preclinical Phase in progress
|
Cleared IND Phase not started
|
Clinical Trials Phase not started
|
HBV non-viral CRISPR/Cas dual gRNA Therapeutic
Discovery/Validation | Preclinical | Cleared IND | Clinical Trials |
---|---|---|---|
Discovery/Validation Phase in progress
|
Preclinical Phase not started
|
Cleared IND Phase not started
|
Clinical Trials Phase not started
|